Cullinan Therapeutics Inc.
Clinical trials sponsored by Cullinan Therapeutics Inc., explained in plain language.
-
New antibody drug shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis early-stage study tests a new drug called CLN-619 in 30 adults with multiple myeloma that has returned or not responded to other treatments. The drug is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New antibody combo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-stage study tests a new drug called CLN-619, given alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. About 440 peopl…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC